Jeito Capital, a Paris, France-based new, independent Private Equity firm dedicated to biotech and biopharma, closed its first fund, Jeito I, at €534m ($630m).
Jeito I received the support from global investors including the European Investment Fund (EIF), the American pension fund Teacher Retirement System of Texas (TRS), and Temasek.
Led by Rafaèle Tordjman, Founder and CEO, Jeito Capital is building a diversified portfolio of biotech and biopharma companies primarily based in Europe with global reach, focused on the treatment of life-threatening diseases. Its investment model provides support to entrepreneurs by a multi-talented team of experts integrated in the investment team across the entire drug development value chain, from translational science to market access and commercialization, providing significant capital in continuity, up to €80m ($100m) in a single company.
Jeito I investments to date include French-based SparingVision and InnoSkel, in the fields of genomic ophthalmology and rare skeletal disorders, respectively, Dutch biotech Neogene Therapeutics in solid tumors, UK-based Pulmocide in severe respiratory diseases, and Swiss-French Alentis Therapeutics in fibrosis and related cancers.
Launched in January 2020, Jeito Capital completed a first funding round of €200m with the strategic support of investors such as Aviva, AXA, the French public investment bank (BPI), BNP Paribas Fortis, the Caisse des Dépôts et des Consignations (CDC), CNP Assurances, Pro BTP, etc. In the following months, Sanofi selected Jeito as its investment into a private French-based fund, investing €50m.
The firm also has a presence the United States.